Impact of Anti-Giardia and Antihelmintic Treatment on Infant Growth in Bangladesh
- Conditions
- Giardiasis
- Interventions
- Drug: Anti-Giardia and antihelmintic treatment (secnidazole or albendazole)Drug: Anti-Giardia treatment only (secnidazole or albendazole)Drug: Control group (placebo)
- Registration Number
- NCT00607074
- Lead Sponsor
- University of Cambridge
- Brief Summary
This longitudinal study aimed to assess whether regular anti-Giardia and antihelmintic treatment improved growth and small intestinal mucosal function of rural Bangladeshi infants.
- Detailed Description
A randomised double-blind controlled intervention of 36 weeks duration was conducted in a rural community located 40kms north-west of Dhaka, the capital of Bangladesh. Infants aged between 3 and 11 months were randomly assigned to either receiving anti-Giardia and antihelmintic treatment, or anti-Giardia treatment only, or a control group receiving placebos. Weight and supine length were recorded every 4 weeks. Every 12 weeks intestinal permeability (L/M ratio), haemoglobin, plasma albumin, alpha-1-acid glycoprotein, immunoglobulin G and Giardia intestinalis specific IgM titre (GSIgM) and eggs of the three common geohelminths and Giardia intestinalis cysts were determined.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 410
- infants living in the study area
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 Control group (placebo) - 1 Anti-Giardia and antihelmintic treatment (secnidazole or albendazole) - 1 Anti-Giardia treatment only (secnidazole or albendazole) -
- Primary Outcome Measures
Name Time Method nutritional status 9 months
- Secondary Outcome Measures
Name Time Method intestinal permeability 9 months
Trial Locations
- Locations (1)
National Institute of Preventive and Social Medicine
🇧🇩Mohakhali, Dhaka, Bangladesh